[go: up one dir, main page]

JPH06501851A - ヒト免疫不全症候ヴィールスに対する痘苗（ワクチン）および治療方法 - Google Patents

ヒト免疫不全症候ヴィールスに対する痘苗（ワクチン）および治療方法

Info

Publication number
JPH06501851A
JPH06501851A JP5501040A JP50104093A JPH06501851A JP H06501851 A JPH06501851 A JP H06501851A JP 5501040 A JP5501040 A JP 5501040A JP 50104093 A JP50104093 A JP 50104093A JP H06501851 A JPH06501851 A JP H06501851A
Authority
JP
Japan
Prior art keywords
virus
infected
recombinant
human
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5501040A
Other languages
English (en)
Japanese (ja)
Inventor
ゲール　ユーゲン　スミス
フランクリン　ボルボヴィッツ
Original Assignee
マイクロジェネシス　インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マイクロジェネシス　インコーポレイテッド filed Critical マイクロジェネシス　インコーポレイテッド
Publication of JPH06501851A publication Critical patent/JPH06501851A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP5501040A 1991-06-11 1992-06-10 ヒト免疫不全症候ヴィールスに対する痘苗（ワクチン）および治療方法 Pending JPH06501851A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71415291A 1991-06-11 1991-06-11
US714,152 1991-06-11
PCT/US1992/004980 WO1992022654A1 (en) 1991-06-11 1992-06-10 Vaccine and treatment method of human immunodeficiency virus infection

Publications (1)

Publication Number Publication Date
JPH06501851A true JPH06501851A (ja) 1994-03-03

Family

ID=24868938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5501040A Pending JPH06501851A (ja) 1991-06-11 1992-06-10 ヒト免疫不全症候ヴィールスに対する痘苗（ワクチン）および治療方法

Country Status (18)

Country Link
EP (1) EP0542998A1 (xx)
JP (1) JPH06501851A (xx)
CN (1) CN1068266A (xx)
AU (2) AU2193192A (xx)
BG (1) BG97519A (xx)
CA (1) CA2087732A1 (xx)
EE (1) EE9400183A (xx)
FI (1) FI930577L (xx)
HU (1) HUT68355A (xx)
IE (1) IE921875A1 (xx)
IL (1) IL102092A (xx)
LT (1) LT3365B (xx)
MX (1) MX9202781A (xx)
PL (1) PL297849A1 (xx)
PT (1) PT100584A (xx)
SK (1) SK18993A3 (xx)
WO (1) WO1992022654A1 (xx)
ZA (1) ZA924150B (xx)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006509039A (ja) * 2002-12-03 2006-03-16 ユニバーシティ オブ マサチューセッツ 多価初代ｈｉｖ−１糖タンパク質ｄｎａワクチンおよびワクチン接種方法
JP2019006817A (ja) * 2011-08-19 2019-01-17 オーストリッチファーマ株式会社 抗体および抗体含有組成物

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40786E1 (en) * 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
CA2179394A1 (en) * 1993-12-23 1995-06-29 Kostas Iatrou Methods of expressing proteins in insect cells and methods of killing insects
US6475491B1 (en) 1995-06-07 2002-11-05 Trimeris, Inc. Treatment of HIV and other viral infections using combinatorial therapy
US6395541B1 (en) 1996-05-23 2002-05-28 The Rockefeller University Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US6077662A (en) * 1996-11-27 2000-06-20 Emory University Virus-like particles, methods and immunogenic compositions
US6214540B1 (en) 1997-03-26 2001-04-10 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US6548631B1 (en) 1997-09-16 2003-04-15 BIOMéRIEUX, INC. Macrophage derived chemokine (MDC) as an anti-viral agent for the treatment and prevention of lentivirus infection
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
US6623741B1 (en) 2000-02-29 2003-09-23 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
AUPS065002A0 (en) 2002-02-20 2002-03-14 Immunaid Pty Ltd Strategy for retroviral immunotherapy
PL1692516T3 (pl) 2003-10-24 2011-05-31 Immunaid Pty Ltd Sposób terapii
GT200800303A (es) 2007-12-24 2009-09-18 Combinacion anti-retroviral
EP2435825B8 (en) 2009-05-27 2015-09-02 Biotempus Limited Methods of treating diseases
CN102961760B (zh) * 2011-09-01 2017-07-18 常州文松生物技术有限公司 重叠肽作为制备皮肤试验和检测特异性细胞免疫的试剂及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006509039A (ja) * 2002-12-03 2006-03-16 ユニバーシティ オブ マサチューセッツ 多価初代ｈｉｖ−１糖タンパク質ｄｎａワクチンおよびワクチン接種方法
US7901690B2 (en) 2002-12-03 2011-03-08 University Of Massachusetts Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
JP2019006817A (ja) * 2011-08-19 2019-01-17 オーストリッチファーマ株式会社 抗体および抗体含有組成物
US11041016B2 (en) 2011-08-19 2021-06-22 Ostrich Pharma Kk Compositions containing anti-HIV ostrich antibodies

Also Published As

Publication number Publication date
WO1992022654A1 (en) 1992-12-23
IL102092A0 (en) 1993-01-14
ZA924150B (en) 1993-02-24
CN1068266A (zh) 1993-01-27
PT100584A (pt) 1993-07-30
EE9400183A (et) 1995-12-15
PL297849A1 (en) 1994-01-24
IE921875A1 (en) 1992-12-16
CA2087732A1 (en) 1992-12-12
LT3365B (en) 1995-07-25
SK18993A3 (en) 1993-10-06
IL102092A (en) 1996-11-14
AU4028895A (en) 1996-02-22
FI930577A0 (fi) 1993-02-10
FI930577L (fi) 1993-03-24
LTIP335A (en) 1995-01-31
AU2193192A (en) 1993-01-12
BG97519A (bg) 1994-03-24
HU9300686D0 (en) 1993-06-28
EP0542998A1 (en) 1993-05-26
HUT68355A (en) 1995-06-28
MX9202781A (es) 1993-04-01

Similar Documents

Publication Publication Date Title
JPH06501851A (ja) ヒト免疫不全症候ヴィールスに対する痘苗（ワクチン）および治療方法
AU727107B2 (en) Hiv envelope polypeptides and vaccine
Earl et al. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140
Murphy et al. Diversity of V3 region sequences of human immunodeficiency viruses type 1 from the Central African Republic
Luo et al. Expression of gag precursor protein and secretion of virus-like gag particles of HIV-2 from recombinant baculovirus-infected insect cells
CH676247A5 (xx)
DE69133242T2 (de) Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
JPH10503933A (ja) 抗原的に標識した非感染性レトロウィルス様粒子
US5747324A (en) Self-assembled, defective, non-self-propagating lentivirus particles
CH675728A5 (xx)
EP1466924B1 (en) Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV
EP0689586B1 (en) Vpr function and activity
JPH01500161A (ja) Ａｉｄｓの原因ウィルスの糖蛋白質、該糖蛋白質の製造方法及びワクチン
CA2033175C (en) Self-assembled, defective, non-self-propagating viral particles
JP2003531865A (ja) Ｄｎａおよびワクシニアウイルスベクターワクチンの組み合わせを用いた免疫原性の改善
Haffar et al. HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles
JPH05505616A (ja) 天然のコンホメーションを保持している精製ｇｐ１２０組成物
Montefiori et al. Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus
Javaherian et al. Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein
JPH02203793A (ja) ヒト免疫不全ウイルスタイプ１のエンベロープ遺伝子から誘導されたポリペプチドを含むワクチン
US20080267989A1 (en) Hiv Gp-41-Membrane Proximal Region Arrayed On Hepatitis B Surface Antigen Particles as Novel Antigens
US20050064392A1 (en) Compositions, methods and kits relating to deletion mutations of immunodeficiency virus gp120 hypervariable regions
SI9200420A (sl) Vakcina proti infekciji, ki jo povzroča človeški virus imunodeficience
HRP921484A2 (en) Vaccine and treatment method of human immunodeficiency virus infection
TWI329647B (en) Vaccines